NONOF — NOVO NORDISK A S
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 353278 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
2026-11-04
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 78,488,000,000 | 61,388,000,000 | 27,061,000,000 | 20,989,000,000 | 594,941,000,000 | 44,482,000,000 | 373,664,000,000 |
| Mar 2026 | 96,823,000,000 | 83,225,000,000 | 59,618,000,000 | 48,557,000,000 | 559,221,000,000 | 21,127,000,000 | 356,156,000,000 |
| Dec 2025 | 79,144,000,000 | 63,996,000,000 | 31,736,000,000 | 26,891,000,000 | 542,902,000,000 | 26,464,000,000 | 348,855,000,000 |
| Sep 2025 | 74,976,000,000 | 57,072,000,000 | 23,682,000,000 | 20,006,000,000 | 512,288,000,000 | 32,084,000,000 | 342,392,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$131,881,000,000
Investing CF
$-83,537,000,000
Financing CF
$-22,242,000,000
CapEx
$-84,092,000,000
Dividends Paid
$-51,975,000,000
Buybacks
$-5,899,000,000
EPS Diluted TTM
$27.65
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$224,164,000,000
Inventory
$51,352,000,000
Receivables
$108,512,000,000
ST Investments
$500,000,000
EBIT TTM
$149,464,000,000
Pretax Income TTM
$148,749,000,000
Interest Exp TTM
$5,551,000,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$329,430,990,848
EBITDA
$173,677,002,752
Free Cash Flow
$37,673,250,816
Enterprise Value
$286,392,877,056
Total Cash
$44,982,001,664
Total Debt
$140,126,994,432
Shares Out
3,344,053,124
Trailing EPS
$4.09
Book Value
$7.74
ROE
59.8%
ROA
18.7%
Div Yield
4.17%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 309,064,000,000 | 127,658,000,000 | 102,434,000,000 | 542,902,000,000 | 348,855,000,000 | 194,047,000,000 | 119,102,000,000 |
| Dec 2024 | 290,403,000,000 | 128,339,000,000 | 100,988,000,000 | 465,630,000,000 | 322,144,000,000 | 143,486,000,000 | 120,968,000,000 |
| Dec 2023 | 232,261,000,000 | 102,574,000,000 | 83,683,000,000 | 314,486,000,000 | 207,925,000,000 | 106,561,000,000 | 108,908,000,000 |
| Dec 2022 | 176,954,000,000 | 74,809,000,000 | 55,525,000,000 | 241,257,000,000 | 157,771,000,000 | 83,486,000,000 | 78,887,000,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.04T | $1169.60 | — |
| JNJ | JOHNSON & JOHNSON | $618.09B | $256.48 | — |
| ABBV | AbbVie Inc. | $481.40B | $272.42 | — |
| MRK | Merck & Co., Inc. | $351.28B | $142.38 | — |
| NVS | NOVARTIS AG | $272.01B | $143.11 | — |
News headlines (Yahoo Finance, 1h cache)
Novo Nordisk (NVO) Raised Its Outlook, Then Aimed for Average Growth
2026-10-09 13:28 · Yahoo
Citi Cuts Novo Nordisk Price Target to DKK 296 on Limited Margin Growth Outlook
2026-10-09 10:52 · Yahoo
Novo Nordisk (CPSE:NOVO B) Gets FDA Review Update As New EASD Data Land
2026-10-09 08:12 · Yahoo
Novo Nordisk stock target cut at Citi on lack of margin growth
2026-10-09 06:36 · Yahoo
UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.
2026-10-09 02:35 · Yahoo
Novo Nordisk’s CEO Was Asked Why His Stock Keeps Falling on Good News: ‘The Stock Market Is Always Right, but With a Bit of a Time Difference’
2026-10-08 15:33 · Yahoo
Scholar Rock Resubmits Apitegromab Marketing Authorisation Application (MAA) to European Medicines Agency (EMA) for Treatment of Children and Adults with Spinal Muscular Atrophy (SMA)
2026-10-08 12:00 · Yahoo
LLY Stock Down 2% in 3 Months: Is the Dip a Buying Opportunity?
2026-10-08 11:31 · Yahoo
Novo Nordisk (NVO) or Eli Lilly (LLY)? Jim Cramer Gives a Clear Response
2026-10-08 03:45 · Yahoo
Novo Nordisk (NVO) Increases Despite Market Slip: Here's What You Need to Know
2026-10-07 20:45 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.